Siemann, J K
Muller, C L
Forsberg, C G
Blakely, R D
Veenstra-VanderWeele, J
Wallace, M T
Article History
Received: 15 September 2016
Revised: 29 December 2016
Accepted: 9 January 2017
First Online: 21 March 2017
Competing interests
: Consulting or Advisory Board: Roche, Novartis, SynapDx. Research funding: Roche, Novartis, SynapDx, Seaside Therapeutics, Forest and editorial stipend: Springer, Wiley for JV-V. The remaining authors declare no conflict of interest.